BioSpace News Archive

Emulate, Inc. today announced its new colon immune cell recruitment application, enabling the most human-relevant preclinical assessment of inflammatory bowel disease (IBD) drug candidates.

Cellarity announced today the appointment of Sandra Horning, M.D., to the Company’s Board of Directors.

Amphastar Pharmaceuticals, Inc. reported results for the three months ended March 31, 2022.

Liminal BioSciences Inc. (NASDAQ: LMNL) (“Liminal BioSciences” or the “Company”), today announced that it plans to report its first quarter 2022 financial results after market close on May 10, 2021.

Invacare Corporation reported results for the quarter ended March 31, 2022.

Rise in global geriatric population and growing prevalence of chronic and acute diseases are some key factors contributing to the global Minimally Invasive Surgical Systems market revenue growth.

Increasing number of people suffering from anaphylaxis and diabetes across the globe, technological advancements in autoinjectors, and rising preference for self-administration of drugs are some key factors expected to drive global Autoinjectors market growth.

Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the first quarter of 2022, reporting continued progress on its oral vaccine candidates.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, “Biogen”) announced today that Eisai has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab.

Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced an amendment to its existing financing agreement with Oberland Capital Management LLC.